AstraZeneca: Phase III Trial Of Imfinzi On Recurrent Or Metastatic Head & Neck Cancer Fails To Meet Goal
LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) said that a late-stage trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer
Source: finanznachrichten.de